CRISPR Therapeutics (NasdaqGM:CRSP) experienced a 15.8% increase in its share price over the past month. While specific recent news on the company was not available to credit for this movement, it's ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 13.29%. Read on to learn why. Crispr Therapeutics AG has seen a notable increase in its stock ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The inducement grant consisted of time-based restricted stock units ("RSUs”) for 33,600 shares of Intellia's common stock, ...

CRISPR Therapeutics CRSP is currently the only company in the world to have secured approval for a CRISPR-based gene therapy ...

Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to ...

Epigenetic changes do not alter the genetic code itself, but by changing how DNA is organized within the cell, epigenetic ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...